Research on personalised medicine Group
Research on personalised medicine
​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​Diabetes is increasing rapidly from 415 million patients in 2015 to 642 million patients by 2040. As a result, it will become the leading disease worldwide, affecting 1 out of 10 persons globally and 3 out of 4 in low and middle income countries.

The World Health Organisation marked World Health Day 2016 as calling for action on diabetes. Despite successful treatment of the inadequate glucose handling, diabetic patients show long-term effects of the disease such as a progressive loss of multiple organ function, in particular in the cardiovascular and renal systems. About half of the diabetic patients are at risk for renal complications associated with a markedly increased disease burden and death rate, the latter even surpassing the death rate in all treated cancer patients. We train and educates in 4 main pillars. We will contribute to the implementation and optimalisatoin of personalised medicine in all of these societal domains.

prominent domains

The major reason for the lack of treatment efficacy is the large variation in individual response to the treatment. Consequently, we are left with a huge unmet need in the treatment of this chronic disease. A huge step forward in chronic diabetes disease management is personalised medicine. The EC has recognised the importance of personalised medicine and has started initiatives in this regard in 2016. The COFUND PROMINENT programme of the Research Institute for Drug Exploration (GUIDE) brings these fields together and introduces personalised medicine for chronic diabetes disease management.

Watch video Scan QR-code

How our research benefits to society

We are focussed at setting up a dedicated doctoral training programme for Early Stage Researchers (ESRs) at the University Medical Center Groningen (UMCG) and the University of Groningen (RUG). We aim to select the best students to become excellently trained researchers, who can perform high quality research, and who subsequently have a major impact on scientific breakthroughs that foster the European society and economy in this field.

EU logo normal reproduction
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No 754425.


Program manager / Group leader
Sieta de Vries

Executive coordinator research
Hiddo Heerspink

Executive coordinator training
Sven van IJzendoorn

University Medical Center Groningen (UMCG)
P.O. Box 196
9700 AD Groningen
The Netherlands

University Medical Center Groningen (UMCG)
Ant. Deusinglaan 1
9713 AV Groningen
The Netherlands